Soluble TL1A has been shown to enhance the proliferation of CD4 + T cells and induce the secretion of interferon (IFN)-γ and granulocyte-macrophage colony stimulating factor (GM-CSF) by activated ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

According to AbbVie, FG-M701 could offer best-in-class functional characteristics compared to what it calls first-generation TL1A antibodies, with the potential to offer “greater efficacy and ...

The drug works by targeting TL1A, the product of a gene expressed in many different inflammatory cells. The double-blind ...

It also signed a license agreement with China’s FutureGen to develop a next-generation anti-TL1A antibody for IBD. Its successful immunology drug Rinvoq is approved for treating both UC and CD ...